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Multiple genes, interacting with the environment, con-
tribute to the susceptibility to type 2 diabetes. We
performed a genome-wide search to localize type 2
diabetes susceptibility genes in a recently genetically
isolated population in the Netherlands. We identified 79
nuclear families with type 2 diabetes who were related
within 13 generations and performed a 770-marker ge-
nome-wide scan search for shared founder alleles.
Twenty-six markers yielded a logarithm of odds (LOD)
score >0.59 (nominal P < 0.05), of which 7 reached LOD
scores >1.17 (nominal P < 0.01). The strongest evi-
dence for a type 2 diabetes locus was at marker D18S63
on chromosome 18p (LOD 2.3, P  0.0006). This region
was investigated further using additional markers. For
one of these markers (D18S1105), we found a signifi-
cant association with type 2 diabetes (odds ratio 6.7
[95% CI 1.5–30.7], P  0.005 for the 97-bp allele, assum-
ing a dominant model), which increased when limiting
the analysis to patients with high BMI (12.25 [2.1–71],
P  0.003). A locus on chromosome 18p in patients with
high BMI was suggested earlier by Parker et al. Our
study is the first to confirm this locus. Diabetes 52:
3001–3004, 2003
Type 2 diabetes has a substantial genetic compo-nent. Although different genes involved in type 2diabetes have been localized (1), the geneticorigin of the disease is unknown for most pa-
tients. It is most likely that a large number of genes are
involved in type 2 diabetes. The effect of these genes may
largely depend on the interaction with other genes and
nongenetic factors. Genes for complex diseases such as
type 2 diabetes are expected to be more easily identified in
isolated populations than in a general outbred population
(2). As a consequence of drift and founder effects, a large
number of patients in isolated populations have likely
inherited the disease susceptibility from a common ge-
netic ancestor. Since adjacent markers on a chromosome
are often transmitted together, patients who have inher-
ited a susceptibility gene from a common ancestor are
likely to share considerable stretches of DNA around the
disease gene, leading to association of multiple adjacent
markers to the disease. These regions can be traced
relatively easily in a genome screen, particularly in popu-
lations of recent isolation (3). Although there is an ongoing
debate whether genetically isolated populations are more
suitable than outbred populations for genetic association
studies, several studies in isolates have been successful.
This concerns studies of complex disorders, such as
multiple sclerosis, hypercholesteremia, and osteoarthritis,
in various isolated populations, including the Finnish and
Icelandic populations and inbred populations such as the
Pima Indians (4–7).
We carried out a study aiming to find new genes
involved in type 2 diabetes in a population of recent
isolation. We ascertained 128 type 2 diabetic patients in an
isolated village in the southwest of the Netherlands. This
village was founded in the middle of the 18th century by
150 people and was isolated until the last few decades
(immigration 5%). From 1848 onward, the population
expanded from 700 to 20,000 inhabitants. We identified 128
patients with type 2 diabetes who derived from 86 nuclear
families. Genealogical information was collected up to 15
generations and revealed that 79 families (117 patients,
91% of all patients) could be traced to a common ancestor
within 13 generations. When drawing 100 samples of
“control subjects” who were randomly selected from our
genealogic database and age and sex matched with study
probands, on average, 38.9  0.43 (45  0.5%) people
could be connected to a common ancestor, with a maxi-
mum of 50 (58%). Thus, the pedigree of the type 2 diabetic
patients suggests that the disease may be in part explained
by a rare mutation segregating in the isolate. In Fig. 1, the
genealogical lineages of these patients are shown based on
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the shortest number of meioses separating them. To
ensure a more homogeneous study population, the analy-
ses in this study were restricted to the 79 related families.
The characteristics of the 117 patients are given in Table 1.
We performed a genome scan on these 117 type 2
diabetic patients and 202 first-degree relatives using 700
short tandem repeat markers. To evaluate statistical evi-
dence for a type 2 diabetes locus, we used a combined
linkage- and association-based approach (see RESEARCH
DESIGN AND METHODS). The 202 first-degree relatives
(spouses, parents, siblings, or children) were included to
obtain control alleles for association analysis and gather
linkage information. Furthermore, empirical P values were
estimated using simulation analysis. A total of 26 markers
showed nominal (maximum logarithm of odds [LOD]
score 0.59, P  0.05) evidence for linkage in presence of
association with type 2 diabetes (Table 2). Seven markers
(D1S2846, D2S323, D3S1270, D3S3681, D6S1569, D14S283,
and D18S63) reached LOD scores 1.17 (nominal P 
0.01). The strongest evidence for a type 2 diabetes locus
was obtained at 18p for marker D18S63 (LOD score 2.3,
nominal P  0.0006). For this marker, the empirical P
value was estimated to be 0.005. This was the only
location with an LOD 2. Also, one pair of markers
located on chromosome 3 (D3S3567 and D3S3521, sepa-
rated by less than 10 cM) yielded an LOD score 0.59.
Between D3S3567 and D3S3521, one additional marker
(D3S1277) showed weak evidence for association (LOD
0.43, P  0.08). Although we cannot exclude a type 2
diabetes gene in this region, the evidence is rather weak
compared with that for locus on 18p.
We explored the most promising region (18p) in more
detail by investigating seven additional markers (Table 3).
Although these analyses cannot be viewed as an indepen-
dent confirmation, they are of interest to refine the region
of interest encompassing the gene. Association of various
additional markers with type 2 diabetes was observed. In
particular, the odds ratio (OR) for the 97-bp allele of
marker D18S1105 was high (6.7 [95% CI 1.5–30.7]) (Table
3). The significance of this finding was high (P 0.005, not
adjusted for multiple testing, dominant model). An evalu-
ation of the ORs for D18S1105 and D18S63 showed that the
effect of the risk-associated allele appears to be dominant
in that the risk of type 2 diabetes was increased for both
homo- and heterozygous individuals. However, the power
of our study was limited, which is indicated by the wide
range of the CIs shown in Table 3. Following Parker et al.
(8), who found evidence for a type 2 diabetes locus in the
same 18p region, we have conducted a separate analysis in
those subjects who were in the upper 25% level of BMI.
Although this substantially reduced the number of pa-
tients, the P value for the DS1105 remained low and the OR
increased for 8 of the 10 markers shown in Table 3.
Although several genetic factors have been identified for
type 2 diabetes, including mutations in the HNF-1, HNF-
1, HNF-4, and IPF-1 genes involved in maturity-onset
diabetes of the young (9), the genetic origin for the
majority of patients with diabetes with adult onset is still
unknown. Linkage studies for loci influencing the risk for
type 2 diabetes have been conducted in a number of
populations (reviewed in 1). In 1996, Hanis et al. (10)
reported significant evidence for linkage of type 2 diabetes
to the distal arm of chromosome 2. Using a linkage-
disequilibrium approach similar to the approach used in
our study, Horikawa et al. (11) demonstrated that suscep-
tibility at this locus is confined to combinations of poly-
morphisms in the gene encoding calpain-10. Our study did
not show evidence for association of markers in the
calpain-10 region to type 2 diabetes. The strongest evi-
dence for a type 2 diabetes locus was obtained at 18p, thus
confirming the findings of Parker et al. (8).
RESEARCH DESIGN AND METHODS
Patients with type 2 diabetes were recruited at local health care centers and
the Diabetes Service Breda, which is a regional clinical and laboratory service
for the region. Since 1990, the Diabetes Service Breda has collected clinical
and biochemical data on 8,000 patients with type 2 diabetes. All patients
FIG. 1. Genealogical lineages of 117 type 2 diabetic patients who could be traced to a common ancestor within 13 generations. The figure is based
on the shortest number of meiosis separating each person from this common ancestor.
TABLE 1
Characteristics of 117 type 2 diabetic patients
n 117
Male/female 47/70
Age at examination (years) 63.5 13.0
Age at onset (years) 57.9 12.3
BMI (kg/m2) 29.8 4.8
Medication
None 25
Oral 72
Insulin 20
Fasting glucose (mmol/l) 8.7 3.2*
Data are means  SD. *Includes subjects using glucose-lowering
medication.
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underwent clinical and laboratory evaluations for their diabetes at regular
3-month intervals. We recruited 160 patients diagnosed with type 2 diabetes
living in the isolated village. The overall participation rate was 80% (n  128).
The mean age at diagnosis of these patients was 57.9 years. All participants
completed a questionnaire on family and medical history, underwent anthro-
pometric and blood pressure measurements, and gave blood samples for DNA
extraction and fasting serum. We applied the American Diabetes Association
criteria for the diagnosis of diabetes to confirm the diagnosis (12). Individuals
who were pregnant at the time of diagnosis or individuals who were insulin
dependent within 1 year after diagnosis were assigned a diagnosis of “un-
known.” The study was approved by the medical ethics committee of the
Erasmus Medical Center, Rotterdam, and written consent was obtained from
TABLE 2
Markers with LOD score 0.59 (P  0.05) in the initial genome scan
Chromosome Map location (cM)* Marker  LOD score PA† PE  SE
1 91.89 D1S2846 0.70 1.50 0.004 0.015 0.009
2 5.4 D2S323 0.66 1.60 0.003 0.010 0.007
3 6.96 D3S1270 0.59 1.30 0.007 0.011 0.008
3 56.69 D3S3567 0.36 0.70 0.036 0.011 0.008
3 63.12 D3S3521 0.23 0.97 0.017 0.005
3 109.22 D3S3681 0.22 1.20 0.009 0.005 0.005
4 33.42 D4S419 0.28 0.82 0.026 0.010 0.007
4 83.02 D4S428 0.27 0.60 0.048 0.032 0.022
4 96.58 D4S398 0.28 0.77 0.030 0.005
4 206.58 D4S413 0.34 0.66 0.041 0.010 0.007
6 141.15 D6S1569 0.39 1.30 0.007 0.005
8 30.5 D8S552 0.46 0.78 0.029 0.005 0.005
9 132.09 D9S1682 0.30 1.00 0.016 0.005 0.005
10 170.94 D10S212 0.56 1.10 0.012 0.010 0.007
11 153.31 D11S925 0.24 0.80 0.027 0.041 0.014
11 138.56 D11S4126 0.59 0.89 0.021 0.005
14 13.89 D14S283 0.33 1.60 0.003 0.005
15 35.95 D15S1012 0.27 0.80 0.027 0.010 0.007
17 36.14 D17S921 0.32 0.66 0.041 0.021 0.010
17 58.25 D17S927 0.36 0.62 0.046 0.010 0.007
18 8.3 D18S63 0.45 2.30 0.001 0.005
18 96.48 D18S68 0.31 1.10 0.012 0.010 0.007
18 114.26 D18S1161 0.35 0.94 0.019 0.005
19 32.39 D19S865 0.26 0.86 0.023 0.005
20 35.51 D20S898 0.32 0.59 0.050 0.015 0.009
21 35.45 D21S1252 0.21 0.83 0.025 0.005 0.005
*Based on Marshfield genetic map. †PA, asymptotic P values; PE, empirical P values.
TABLE 3
Association of markers in the chromosome 18p region with type 2 diabetes using a set of 71 case and 34 control subjects.
Marker
Position
(kb)* N†
Associated
allele
(mobility)
Frequency OR (95% CI) [P value FET‡]
Case
subjects
Control
subjects Heterozygous Homozygous Dominant
d18s1140 1,018 5 268 0.75 0.68 1.10 (0.26–4.57) [1.000] 1.67 (0.41–6.70) [0.476] 1.40 (0.37–5.33) [0.726]
d18s59 1,063 7 166 0.25 0.20 1.75 (0.70–4.38) [0.267] 1.13 (0.19–6.66) [1.000] 1.64 (0.69–3.88) [0.291]
d18s1105 2,251 5 97 0.17 0.03 6.39 (1.39–29.34) [0.009] [1.000]§ 6.70 (1.46–30.67) [0.005]
d18s476 2,595 5 277 0.56 0.46 0.91 (0.30–2.70) [1.000] 2.20 (0.58–8.30) [0.319] 1.21 (0.43–3.44) [0.789]
d18s1098 3,287 4 171 0.42 0.40 1.34 (0.54–3.35) [0.640] 1.08 (0.32–3.63) [1.000] 1.27 (0.54–2.99) [0.590]
d18s481 3,484 7 185 0.11 0.08 1.35 (0.44–4.16) [0.783] [1.000] 1.45 (0.47–4.44) [0.596]
d18s63 3,860 6 86 0.44 0.32 2.59 (1.04–6.46) [0.063] 2.32 (0.62–8.70) [0.345] 2.53 (1.07–5.98) [0.045]
d18s459 3,956 7 140 0.20 0.14 1.87 (0.70–4.97) [0.248] 1.14 (0.10–13.17) [1.000] 1.78 (0.70–4.52) [0.264]
d18s1154 4,317 6 271 0.32 0.27 1.03 (0.43–2.46) [1.000] 2.06 (0.39–10.80) [0.480] 1.16 (0.51–2.66) [0.833]
d18s1132 5,046 5 122 0.46 0.36 1.20 (0.46–3.10) [0.810] 1.98 (0.64–6.08) [0.282] 1.46 (0.62–3.41) [0.393]
Using only 25%
most obese
subjects
d18s1140 1,018 5 268 0.83 0.68 0.86 (0.07–10.67) [1.000] 2.75 (0.27–28.04) [0.626] 1.87 (0.19–18.27) [1.000]
d18s59 1,063 7 166 0.28 0.20 3.14 (0.90–11.03) [0.113] 0.00 [1.000] 2.57 (0.76–8.75) [0.215]
d18s1105 2,251 5 97 0.27 0.03 10.5 (1.77–62.44) [0.008] [0.243] 12.25 (2.11–70.99) [0.003]
d18s476 2,595 5 277 0.64 0.46 1.31 (0.21–8.18) [1.000] 4.20 (0.59–30.10) [0.197] 2.00 (0.36–11.22) [0.692]
d18s1098 3,287 4 171 0.43 0.40 3.18 (0.73–13.92) [0.180] 0.72 (0.62–8.46) [1.000] 2.48 (0.59–9.47) [0.324]
d18s481 3,484 7 185 0.07 0.08 0.86 (0.15–5.04) [1.000] [1.000] 0.86 (0.15–5.04) [1.000]
d18s63 3,860 6 86 0.47 0.32 4.51 (1.04–19.66) [0.052] 2.67 (0.33–21.73) [0.562] 4.08 (0.98–17.03) [0.063]
d18s459 3,956 7 140 0.10 0.14 0.89 (0.20–4.07) [1.000] 0.00 [1.000] 0.78 (0.18–3.48) [1.000]
d18s1154 4,317 6 271 0.33 0.27 1.04 (0.28–3.82) [1.000] 2.43 (0.28–20.82) [0.574] 1.21 (0.36–4.12) [1.000]
d18s1132 5,046 5 122 0.50 0.36 1.50 (0.37–6.14) [0.724] 2.50 (0.53–11.89) [0.423] 1.83 (0.52–6.46) [0.375]
Markers used in the original scan are in bold. *Based on Celera physical map; †Alleles at marker locus; ‡P value from Fisher exact test (FET),
not adjusted for multiple testing; §OR could not be calculated (missing data).
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all subjects. From 47 spouses of probands, 34 agreed to donate blood for DNA
studies.
Collection of genealogical information. To determine which of the sub-
jects descended from the original founders of the isolated village, a genealog-
ical search was completed for each patient using church and municipal
records of births, marriages, and deaths. Genealogical lineages for each
patient were traced back 15 generations. Patients were linked to each other
under the restriction of connecting as many individuals as possible to a
common ancestor.
Genotyping. The genome screen was performed using 770 markers covering
the whole genome. No gap was 18.7 cM and no more than 21 gaps (2.7%)
were 10 cM.
Statistical analysis. A stepwise procedure was used in the analyses. Earlier,
we used this approach in a study of type 1 diabetes (13). First, a test for
linkage disequilibrium of single markers with diabetes was performed. The
test used is based on a modification of the method described by Terwilliger
(14) and assumes that one marker allele will be overrepresented on chromo-
somes that carry the disease mutation when many of these chromosomes
descend from a single ancestor. The proportion of disease chromosomes with
this ancestral allele is represented by the  parameter. It is not known a priori
which marker allele will be the overrepresented allele, and therefore the test
considers each of the marker alleles separately as potential founder alleles.
Consequently, a total likelihood is obtained for a given value of  by
computing the likelihood on the data for each potential founder allele and
summing those likelihoods, which are weighted for the population frequency
of the respective founder allele. As this procedure implies estimation of a
single parameter, , which is restricted to be positive or zero, under the null
hypothesis the test statistics are distributed as one-tailed 2 test with 1 degree
of freedom (14). While the procedure was originally applied to genotype data
in samples of affected and unaffected individuals, it can also be used to
calculate likelihood for pedigree data. The approach we adopted is based on
the standard model-based methodology, as realized in the LINKAGE package
of programs. However, the model was extended to allow for association by
incorporating the  parameter into the model (15). In the estimation proce-
dure the recombination fraction was fixed at 0.01 and the disease gene
frequency was kept constant at 2.5%, a dominant model was assumed (Fig. 1).
Subjects were assigned to one of the age-based liability classes, which are
derived from the age-of-onset distribution of patients with type 2 diabetes
from the Rotterdam study, a population-based cohort study in the Nether-
lands. In this study, an LOD score 0.59 (corresponding to nominal P  0.05)
was used as a threshold to select markers for further discussion. To obtain
empirical P values, a simulation study was conducted. For every marker listed
in Table 2, we used MERLIN (16) to generate 200 samples. Every sample was
then reanalyzed using our approach.
In the second phase, additional markers were accessed for the region
surrounding D18S63, which showed the strongest evidence for association in
the initial genome scan. A case-control analysis was performed to test for
association of additional markers with type 2 diabetes. For the case-control
analysis, one proband was selected per family. We used healthy spouses of
probands as control subjects. The relative risk for each ancestral allele was
estimated as an OR with a 95% CI.
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